Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review

This is the authors' abstract. We don't add key points for this paper.

The quantity and quality of postapproval clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of limited evidence, with few controlled studies published after approval that confirmed efficacy using clinical outcomes for the original FDA approved indication.